Literature Highlights - January 2023

systematic review, targeted treatments, biologics, clinical trial, belimumab, anifrolumab, Bruton’s Tyrosine Kinase, BTK, inhibitor, evobrutinib, SLE, systemic lupus erythematosus, dose-ranging, pregnancy, obstetric comorbidities, , childhood-onset SLE (cSLE), treatment, safety, CD40 ligand, dapirolizumab pegol, exposure-response, population pharmacokinetics

more…

Clear Search

Showing 1 result for “Urowitz MB”.

May 2022

Impact of belimumab on organ damage in systemic lupus erythematosus

Arthritis Care Res (Hoboken). 2022 Epub ahead of print doi: 10.1002/acr.24901

Review of clinical trial and real-world data on the effects of belimumab on organ damage in adult patients with SLE shows that belimumab reduces key drivers of organ damage, decreases organ damage progression and, in those with lupus nephritis (LN), decreases renal-related events.

more…